Please assess the completion status of the following clinical trial:

Trial Title: HIV Risk Reduction in Subutex Injectors in Tbilisi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* current opioid dependence;~* injecting buprenorphine 10 or more times in the last 30 days;~* between 25 and 50 years of age;~* buprenorphine and/or opiate positive urine test;~* not on methadone maintenance in last 4 weeks;~* stable address within Tbilisi and not planning to move;~* home or cellular phone number where can be reached;~* able to provide name of family member who knows whereabouts;~* willingness and ability to give informed consent.~Exclusion Criteria:~* currently dependent on alcohol, benzodiazepines or other CNS depressants;~* legan charges with impending incarceration;~* plans to move from Tbilisi within next 6 months;~* current participation in another treatment study;~* serious medical problems that would impair or make hazardous ability to participate;~* active TB;~* currently psychotic/suicidal;~* uncontrolled seizure disorder.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Methadone maintenance for 12 weeks (Type: ACTIVE_COMPARATOR): Methadone maintenance for 12 weeks as compared to 12 weeks maintenance on Suboxone.
- buprenorphine-naloxone (Suboxone) (Type: ACTIVE_COMPARATOR): 12 weeks of maintenance on buprenorphine-naloxone (Suboxone) at daily doses ranging from 8 to 32 mg with counseling

Based on this trial design, predict the completion outcome and termination type (if applicable).